XenoPort, Inc. (NASDAQ:XNPT) reported Q1 EPS of ($0.36), $0.04 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $3.4 million versus the consensus estimate of $3.86 million. XenoPort, Inc. (NASDAQ:XNPT) net profit margin is – and weekly performance is 8.60%. On last trading day company shares ended up $4.04. Analysts mean target price for the company is $6.25. XenoPort, Inc. (NASDAQ:XNPT) distance from 50-day simple moving average (SMA50) is -9.91%.
ImmunoGen, Inc. (NASDAQ:IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, provided information on the data presentations on Company and partner compounds to be made at the 2014 American Society of Clinical Oncology (ASCO) annual meeting, which will be held May 30-June 3 in Chicago, IL. New clinical data are being presented on ImmunoGen wholly owned compounds, IMGN529 and IMGN853, as well as on partner compounds SAR3419, SAR650984 and Kadcyla® (ado-trastuzumab emtansine). ImmunoGen, Inc. (NASDAQ:IMGN) shares advanced 5.99% in last trading session and ended the day on $11.77. IMGN return on assets is -38.90%.ImmunoGen, Inc. (NASDAQ:IMGN) quarterly performance is -32.67%.
TG Therapeutics Inc. (NASDAQ:TGTX)‘s stock had its “focus list” rating reiterated by equities research analysts at Roth Capital in a research note issued to investors on Thursday. TG Therapeutics, Inc. (NASDAQ:TGTX) shares moved up 14.02% in last trading session and was closed at $6.10, while trading in range of $5.51 – $6.39. TG Therapeutics, Inc. (NASDAQ:TGTX) year to date (YTD) performance is 56.41%.
Curis, Inc. (NASDAQ:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, on 23 may announced that its collaborators, Roche/Genentech and Debiopharm Group™ will present results from clinical studies of Erivedge® and Debio 0932, respectively, at the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) to be held from May 30th to June 3rd in Chicago, IL. Curis, Inc. (NASDAQ:CRIS) ended the last trading day at $1.94. Company weekly volatility is calculated as 7.15% and price to cash ratio as 2.88.Curis, Inc. (NASDAQ:CRIS) showed a positive weekly performance of 5.43%.
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) announced on 20 may the establishment of a strategic alliance with Pathology, Inc. in Torrance, Calif., that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years. On last trading day company shares ended up $37.19.